Abby Reinhard

Investigators suggest recognition of predictors can aid in directing future clinical trials, as well as inform early therapeutic decisions in this patient population.

Monthly focal seizure frequency was reduced from baseline at all 3 dose levels of the differentiated Kv7 potassium channel modulator, compared to placebo.

Data from 31,052 patients on the German Multiple Sclerosis Register were analyzed in the case-control study.

Application follows the results of 2 independent, identical phase 3 trials, ULTIMATE 1 and 2, which assessed the TG Therapeutics anti-CD20 antibody in more than 1000 patients.

Findings from studies of the neuromuscular treatments were presented by at the 2021 World Muscle Society Virtual Congress, September 20-24.

When used for at least 30 days, it was reported that patients with essential tremor reported improvement in tremor power following 54% of sessions.

Susana Vacas, MD, PhD, discussed a recent article that outlined postoperative neurocognitive disorders and the association with anesthesia in older adults undergoing surgery.

The study is the first to provide data from all Latin American countries, further identifying geographic-resultant limitations of access to technology and therapy for NMOSD.

Jess Holguin, OTD, OT/L, spoke on the unique role occupational therapists can play for patients with neuromuscular and movement disorders.

Data from the STRIDE patient registry showed that treatment was also associated with a delay in pulmonary function decline for those with Duchenne muscular dystrophy.

Following MDS 2021, we compiled a roundup of some of our discussions with experts in the Parkinson disease and movement disorders space in one convenient location.

Lucas M. Donovan, MD, MS, discussed key takeaways from a recent study evaluating the integration of telehealth during the COVID-19 pandemic.

Data suggest that certain activities of daily living are more prevalent depending on whether the caregiver is a man or a woman.

Helen Colquhoun, MD, vice president of early development at Sage Therapeutics, commented on results from a phase 2 study in which patients receiving SAGE-324 showed a significant decrease in ET.

Data were collected from the MDS’s membership worldwide, assessing current practices, concerns, and barriers to genetic testing.

Data found that synchronic dance classes conducted through Zoom may be particularly effective for patients who live remotely.

Patients were evaluated at day 29 for change in TETRAS item 4 score change from baseline.

Women with perimenstrual migraine attacks may also be at increased risk of medication overuse.

Investigators noted the psychiatric adverse effects of treatment with medical cannabis, requiring patient monitoring after initiation.

Data from the PRIME-NL study showed stressors resulting from the pandemic impacted depression, anxiety, and quality of life.

Participants in the pilot study saw improvements in short-term memory, attention, and executive functioning.

Initiated by Biogen, the study will evaluate the effectiveness of the treatment in patients previously treated with risdiplam (Evrysdi; PTC Therapeutics).

Investigators found that preschool children had fewer sleep disturbances than older children during home confinement.

Longboard Pharmaceuticals plans to initiate a phase 1b/2a trial to determine the efficacy of the 5-HT2c receptor superagonist in patients with developmental and epileptic encephalopathies.

Joshua Katz, MD, commented on the possibility of an extra vaccine dose for patients with MS and experts’ hope to improve antibody response among the immunocompromised.

Raman Malhotra, MD, president of the American Academy of Sleep Medicine, discussed the initiative, which emphasizes the importance of healthy sleep for students.

Jennifer Majersik, MD, MS, commented on how the AAN, as well as current neurologists and specialists, can help generate interest in the field of neurology to meet patient needs.

Additional functional outcomes and gait analysis showed mixed results when using botulinumtoxinA in those with CP.

Jennifer Majersik, MD, MS, division chief of vascular neurology at the University of Utah, discussed contributing factors to the neurologist shortage, as well as ongoing efforts to increase interest in the field.

Investigators identified a potential dose-response relationship between lower systolic blood pressure and rate CPAP-adherence rates in those with both OSA and type 2 diabetes.